Venus Remedies Limited (NSE:VENUSREM)
896.60
+35.55 (4.13%)
Apr 2, 2026, 3:29 PM IST
Venus Remedies Revenue
Venus Remedies had revenue of 1.80B INR in the quarter ending December 31, 2025, with 1.92% growth. This brings the company's revenue in the last twelve months to 7.03B, up 8.45% year-over-year. In the fiscal year ending March 31, 2025, Venus Remedies had annual revenue of 6.48B with 7.72% growth.
Revenue (ttm)
7.03B
Revenue Growth
+8.45%
P/S Ratio
1.71
Revenue / Employee
5.41M
Employees
1,298
Market Cap
12.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.48B | 464.37M | 7.72% |
| Mar 31, 2024 | 6.01B | 459.40M | 8.27% |
| Mar 31, 2023 | 5.56B | -446.71M | -7.44% |
| Mar 31, 2022 | 6.00B | 520.57M | 9.50% |
| Mar 31, 2021 | 5.48B | 2.07B | 60.90% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 17.60B |
| Solara Active Pharma Sciences | 12.55B |
| Windlas Biotech | 8.68B |
| Orchid Pharma | 8.11B |
| RPG Life Sciences | 6.74B |
| Ind-Swift Laboratories | 5.94B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.85B |
Venus Remedies News
- 11 months ago - Venus Remedies renews GMP certification from Ukraine’s SMDC for Baddi facility - Business Upturn
- 1 year ago - Venus Remedies shares jump 11% after US FDA grants QIDP status to novel antibiotic VRP-034 - Business Upturn
- 1 year ago - Venus Remedies gets US FDA grants QIDP status to novel polymyxin B formulation VRP-034 - Business Upturn
- 1 year ago - Venus Remedies secures exclusive rights for MET-X clinical development in India - Business Upturn
- 1 year ago - Venus Remedies shares surge 10% after EU GMP Certification renewal - Business Upturn
- 1 year ago - Venus Remedies successfully renews EU GMP certification, reinforcing its European market presence - Business Upturn
- 1 year ago - Venus Remedies stock jumps 4% after receiving GMP certification for Antibiotic facility - Business Upturn
- 1 year ago - Venus Remedies shares surge 6% on Pemetrexed marketing authorization in Philippines - Business Upturn